LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Relay Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

4.54 12.1

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.1

Max

4.72

Galvenie mērījumi

By Trading Economics

Ienākumi

6.7M

-70M

Pārdošana

-7M

677K

Peļņas marža

-10,395.126

Darbinieki

197

EBITDA

8M

-77M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+231.96% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

74M

700M

Iepriekšējā atvēršanas cena

-7.56

Iepriekšējā slēgšanas cena

4.54

Ziņu noskaņojums

By Acuity

50%

50%

167 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Relay Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 18. sept. 23:56 UTC

Karstas akcijas

Stocks to Watch: FedEx, 22nd Century, Scholastic

2025. g. 18. sept. 22:01 UTC

Galvenie tirgus virzītāji

22nd Century Group Shares Gain on Debt Repayment, New Capital

2025. g. 18. sept. 20:51 UTC

Iegādes, apvienošanās, pārņemšana

UPS Terminates Plan to Buy Estafeta

2025. g. 18. sept. 20:31 UTC

Peļņas

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

2025. g. 18. sept. 20:26 UTC

Peļņas

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

2025. g. 18. sept. 23:43 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 18. sept. 23:43 UTC

Tirgus saruna

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

2025. g. 18. sept. 23:43 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 18. sept. 23:40 UTC

Tirgus saruna

Gold Edges Lower Amid Cautious Mood -- Market Talk

2025. g. 18. sept. 23:31 UTC

Tirgus saruna

FedEx Says U.S. Demand Is Resilient -- Market Talk

2025. g. 18. sept. 22:03 UTC

Peļņas

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

2025. g. 18. sept. 22:01 UTC

Peļņas

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

2025. g. 18. sept. 21:56 UTC

Peļņas

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

2025. g. 18. sept. 21:54 UTC

Peļņas

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

2025. g. 18. sept. 21:48 UTC

Peļņas

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

2025. g. 18. sept. 21:47 UTC

Peļņas

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

2025. g. 18. sept. 21:17 UTC

Peļņas

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

2025. g. 18. sept. 21:07 UTC

Peļņas

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

2025. g. 18. sept. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 18. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 18. sept. 20:50 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2025. g. 18. sept. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 18. sept. 20:22 UTC

Iegādes, apvienošanās, pārņemšana

UPS Cites Inability of All Closing Conditions to Be Satisfied

2025. g. 18. sept. 20:22 UTC

Iegādes, apvienošanās, pārņemšana

United Parcel Service Terminates Plan to Buy Estafeta

2025. g. 18. sept. 20:20 UTC

Iegādes, apvienošanās, pārņemšana

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

2025. g. 18. sept. 20:18 UTC

Peļņas

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

2025. g. 18. sept. 20:18 UTC

Peļņas

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

2025. g. 18. sept. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 18. sept. 20:07 UTC

Peļņas

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

2025. g. 18. sept. 20:03 UTC

Peļņas

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Salīdzinājums

Cenas izmaiņa

Relay Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

231.96% augšup

Prognoze 12 mēnešiem

Vidējais 13.71 USD  231.96%

Augstākais 19 USD

Zemākais 4 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Relay Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

9 ratings

7

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

2.88 / 3.285Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

No Evidence

Noskaņojums

By Acuity

167 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat